Navigation Links
Aequus BioPharma Appoints Ronald J. Berenson, M.D. President and CEO
Date:12/10/2012

SEATTLE, Dec. 10, 2012 /PRNewswire/ -- Aequus BioPharma, a majority owned subsidiary of Cell Therapeutics, Inc., announced today that Ronald J. Berenson, M.D. was appointed President and CEO of Aequus. In his new position, Dr. Berenson will expand business and product development opportunities for Aequus' GlycoPolymer technology. Aequus is currently developing its GlycoPolymer technology aimed at creating novel biopharmaceuticals with improved pharmacokinetic properties that require less frequent injections than current therapies.

Dr. Berenson has more than 20 years of senior management experience in biotechnology, and was most recently an Entrepreneur in Residence at the University of Washington. He previously co-founded and served as President and CEO of HemaQuest Pharmaceuticals during the company's first three years, successfully ushering the company's programs into early clinical development of its lead compounds. His background also includes senior executive roles at numerous oncology-focused biotechnology companies, including Founder, Director, President and CEO of Xcyte Therapies, Inc. (which merged with Cyclacel), and Founder, Director, Executive Vice President, Chief Medical Officer and Chief Scientific Officer for CellPro, Inc. (CellPro). At CellPro, he was responsible for regulatory submissions that resulted in the U.S. Food and Drug Administration's (FDA) approval of CellPro's lead product, which was the first FDA-approved biological product in cell therapy. Since 2001, he has been on the Board of Ambassadors of the Fred Hutchinson Cancer Center. Dr. Berenson also has contributed to over 90 publications and holds 10 US patents. He completed his oncology training at Stanford University Medical Center, M.D. from Yale Medical School and obtained his B.S. from Stanford University.

"There are more than 100 therapeutic proteins on the market, and they represent one of the fastest growing classes of drugs today. Patient convenience and compliance continue to be issues with therapeutic proteins due to the need for frequent injections," said Dr. Berenson. "I believe that Aequus's novel approach could address these challenges with the potential to be applied to a wide spectrum of therapeutics."

In May 2012, Aequus reported proof of concept data on AQB-101, its novel hG-CSF-based therapeutic protein candidate that utilizes the GlycoPolymer technology approach. The AQB-101 glycoprotein possesses a plasma half-life that is comparable to PEGylated hG-CSF (Neulasta®), and significantly prolonged compared to the native form of hG-CSF (Neupogen®). 

About GlycoPolymer Technology

Aequus' modular GlycoPolymer technology represents a platform for efficiently creating "glycoengineered" protein-based biotherapeutics. Many protein biotherapeutics are on the market, but suffer from short half-lives, and thus require very frequent injections. By increasing the half-life of proteins, Aequus' technology offers the potential to create longer acting therapeutics, which can be administered much less frequently. This is expected to improve patient convenience and thus compliance leading to improved efficacy and clinical outcomes. The technology genetically ligates an external amino acid domain to a therapeutic protein or peptide candidate that results in additional N-linked glycosylation sites on the therapeutic. Additional N-linked glycan chains increase the plasma half-life and thus its duration of activity. The modular GlycoPolymer technology provides a more technically straightforward and predictable approach to extend the plasma half-life of a protein compared to the previous approaches designed to engineer novel glycosylation sites into proteins.

About Aequus BioPharma, Inc.

Headquartered on Bainbridge Island, WA, Aequus is a biopharmaceutical company committed to streamlining the development and manufacture of novel and "follow-on" therapeutic protein drugs.  Aequus is a majority owned subsidiary of Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC).

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Aequus' modular GlycoPolymer technology (including, without limitation, the drug candidate AQB-101) include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with glycoengineered protein-based biotherapies (including, without limitation, AQB-101), in particular including, without limitation, that Aequus application of modular GlycoPolymer technology to biologically active proteins and peptides may not facilitate the development of therapeutic protein-based drugs that require less frequent dosing and offer improved patient convenience; that AQB-101 may not demonstrate the utility of the GlycoPolymer technology platform; determinations by regulatory, patent and administrative governmental authorities; CTI's and Aequus ability to continue to raise capital as needed to fund their operations; competitive factors; technological developments; costs of developing, producing and selling Aequus product candidates; and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, Aequus and CTI do not intend to update or alter such forward-looking statements whether as a result of new information, future events, or otherwise.

Contact:

Ronald Berenson, M.D.
206-790-1094
rberenson@aequusbio.com


'/>"/>
SOURCE Aequus BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
2. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
3. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
6. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
8. S1 Biopharma Expands Focus to Include Male Sexual Health
9. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
10. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
11. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... Israel , May 31, 2016 CollPlant ... proprietary plant-based rhCollagen technology for tissue repair products - ... Scientist of Israel,s Ministry of ... million development project for 2016. The Chief Scientist,s grant amount ... authorized grant, which totaled NIS 4.7 million.  ...
(Date:5/31/2016)... PUNE, India , May 31, 2016 ... 2016" market research report with comparative analysis of Asthma ... mechanism of action (MoA), route of administration (RoA) and ... and press releases. It also reviews key players involved ... on late-stage and discontinued projects. Complete report ...
(Date:5/30/2016)... 30, 2016 According to ... Services Market by Type (Stability, Raw Materials, Method ... User (Pharmaceutical Companies, Medical Device Companies) - Global ... witnessed healthy growth during the last decade and ... 11.3% between 2016 and 2021 to reach USD ...
Breaking Medicine Technology:
(Date:5/31/2016)... Linda, CA (PRWEB) , ... ... ... an approach to healthcare that considers individuals’ genetic characteristics and the physical ... and precision therapy work in sync. In personalized medicine, diagnosing an individual’s ...
(Date:5/31/2016)... ... May 31, 2016 , ... St. Joseph Medical ... health information exchange, which enables physicians at SJMC’s two hospital campuses, downtown and ... participating organizations in the exchange. SJMC’s membership in the health information exchange underscores ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... back to particular advertising campaigns, to monitor the performance of sales and support ... maximize conversions and revenue. The software allows customers to record, transcribe, route, document, ...
(Date:5/31/2016)... ... May 31, 2016 , ... The Global Wellness Summit (GWS), ... on the future of wellness, travel, spa and beauty in Europe. The organization asked ... companies to leading economists and researchers - to forecast where wellness is headed in ...
(Date:5/31/2016)... ... ... Interest is on the rise for using the CRISPR-Cas9 system for functional ... hit validation. A key reason may be that high-throughput synthesis—combined with a proprietary algorithm ... collections in arrayed formats. , Arrayed crRNA screens have the advantage ...
Breaking Medicine News(10 mins):